论文部分内容阅读
欧洲和加拿大学者最近通过研究证实,用核苷类逆转录酶抑制剂abacavir取代三联抗逆转录病毒治疗方案中的蛋白酶抑制剂,能够有效地治疗HIV感染,并具有良好的耐受性。由于并非所有的HIV感染者都能耐受长期的蛋白酶抑制剂治疗方案,研究人员开始探索用abacavir取代蛋白酶抑制剂的效果。他们以211名至少接受过为期6个月的蛋白酶抑制剂方案治疗、血浆HIV-1RNA浓度在可探测水平以下的HIV感染者为研究对象,随机将其分为两组:一组继续接受该方案治疗（106人）,另一组则用abacavir取代蛋白酶抑制剂（105人）,
Recent studies by European and Canadian scholars confirm that the use of the nucleoside reverse transcriptase inhibitor abacavir to replace protease inhibitors in triple antiretroviral regimens is effective in treating HIV infection and is well tolerated. As not all HIV-infected individuals are able to tolerate long-term protease inhibitor regimens, researchers are beginning to explore the effect of substituting abacavir for protease inhibitors. They were randomized to receive treatment with 211 protease inhibitor regimens for at least 6 months and HIV-1 RNA concentrations below detectable levels in HIV-1 patients, who were randomized to receive either a (106), and the other group replaced abacavir with protease inhibitors (105)